NVS logo

NVS

Novartis AG

$150.62
-$1.39(-0.91%)
73
Overall
80
Value
81
Tech
60
Quality
How is this score calculated?
Market Cap
$287.06B
Volume
884.18K
52W Range
$111.06 - $170.46
Target Price
$147.95
Order:

Income Statement

MetricTrendChart
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
2025
Dec
REVENUE
Total Revenue
$89.5B$95.0B$97.3B$51.6B$50.5B$45.4B$50.3B$54.5B
Total Revenue
$89.5B$95.0B$49.9B$44.0B$43.5B$46.7B$51.7B$56.7B
COST OF GOODS SOLD
Cost of Revenue
$-14.5B$-14.4B$-15.1B$11.7B$11.6B$12.5B$12.8B$13.7B
GROSS PROFIT
Gross Profit
$31.6B$34.3B$34.8B$32.2B$31.9B$34.2B$38.9B$43.0B
OPERATING EXPENSES
Operating Expenses
$24.8B$27.2B$26.4B$-25.3B$-27.1B$24.5B$24.4B$25.3B
Research & Development
$8.5B$9.4B$9.0B$9.5B$10.0B$11.4B$10.0B$11.2B
Research Expense
$8.5B$9.4B$9.0B----$11.4B$10.0B--
Selling, General & Administrative
$13.7B$14.4B$14.2B$14.9B$14.3B$12.5B$12.6B$13.2B
Selling & Marketing Expenses
$13.7B$14.4B$14.2B----$12.5B$12.6B$13.2B
General & Administrative Expenses
$16.5B--------------
Salaries & Wages
$-1.0B--------------
Depreciation & Amortization
--$-305.0M$-330.0M----------
Depreciation & Amortization
$472.0M$-305.0M$-330.0M----------
Other Operating Expenses
$2.6B$3.4B$3.2B$-895.0M$-2.9B$610.0M$1.8B$895.0M
OPERATING INCOME
Operating income
$50.2B$53.4B$55.8B$11.7B$9.2B$9.7B$14.5B$17.6B
EBITDA
$15.0B$9.8B$17.2B$30.9B$14.7B$9.9B$14.5B$17.6B
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$932.0M$850.0M$869.0M$787.0M$800.0M$792.0M$1.1B$1.3B
Interest Income Operating
$142.0M--------------
Intinc
$292.0M$245.0M$91.0M$71.0M$379.0M$219.0M$145.0M--
Net Non-Operating Interest Income/Expense
$-746.0M$-805.0M$-947.0M$-891.0M$-633.0M$-573.0M$-1.1B$-1.3B
Gain on Sale of Securities
--------$-184.0M------
Other Income/Expense
$-20.7B$-2.7B$-10.5B$-15.3B$193.0M$-227.0M----
Other Special Charges
$14.2B$2.0B$1.7B$1.9B$805.0M------
SPECIAL ITEMS
Restructring And Mn A Income
$3.2B--------------
Special Income Charges
$-603.0M$11.7B$702.0M----------
Impairment of Capital Assets
--$-37.0M------------
PRE-TAX INCOME
EBIT
$15.0B$9.8B$10.7B$25.3B$8.0B$9.9B$14.5B$17.6B
Pre-Tax Income
$14.1B$8.9B$9.9B$26.1B$8.4B$9.1B$13.4B$16.4B
INCOME TAX
Tax Provision
$-11.5B$-5.4B$1.8B$1.6B$1.1B$-551.0M$1.7B$2.4B
NET INCOME
Net Income
$81.4B$81.5B$8.1B$24.0B$7.0B$15.9B$11.7B$14.0B
Net Income (Continuing Operations)
$81.4B$81.5B$71.6B$46.8B$5.7B$9.7B$11.7B$14.0B
Net Income (Discontinued Operations)
$81.4B$81.5B$8.1B$24.0B$7.0B$15.9B$11.7B$14.0B
Net Income (Common Stockholders)
$81.4B$81.5B$8.1B$24.0B$7.0B$15.9B$11.7B$14.0B
Normalized Income
----------$8.6B$13.2B$16.2B
TOTALS
Total Expenses
$10.3B$12.8B$11.2B$11.3B$12.5B$37.0B$37.2B$39.0B
SHARE & EPS DATA
Average Shares Outstanding
$2.3B$2.3B$2.3B$2.2B$1.8B$2.1B$2.0B--
Average Shares Outstanding (Diluted)
$17.8B$16.1B$20.4B$11.5B$1.8B$2.1B$2.0B--
Shares Outstanding
$2.3B$2.3B$2.3B$2.2B$2.1B$1.9B$1.9B$1.9B
Basic EPS
$5.44$5.12$3.55$10.71$3.19$7.15$5.92--
Basic EPS (Continuing Operations)
--$3.12$3.55$10.71--$7.15$5.92--
Diluted EPS
$5.38$5.06$3.52$10.63$3.17$7.1$5.87--
Diluted EPS (Continuing Operations)
--$3.08$3.52$10.63--$7.1$5.87--
Dividend Per Share
--------$3.46$3.2$3.3--
OTHER METRICS
Acquired In Process Rn D
$664.0M$11.7B------------
Acquired In Process Rn D Income
----$8.1B----------
Allowances For Construction
$218.0M--------------
Basic Discontinuous Operations
--$2------------
Depletion
$472.0M--------------
Development Expense
$167.0M--------------
Diluted Discontinuous Operations
--$1.98------------
Earnings from equity interest
$6.4B$659.0M$673.0M$15.3B$-9.0M$-13.0M----
Earnings From Equity Interest Net Of Tax
$6.4B$659.0M$673.0M$15.3B$-9.0M$-13.0M----
Gain On Sale Of Business
--$4.7B------------
Gain On Sale Of P P E
$12.6B--------------
Gains Loss On Disposal Of Discontinued Operations
$-186.0M$4.6B------------
Insurance And Claims
$823.0M--------------
Interest Expense Operating
$855.0M--------------
Minority Interests
$3.0M$5.0M$1.0M$3.0M--$-4.0M$-2.0M$17.0M
Net Income Discontinuous Operations
$-186.0M$9.2B------$6.3B----
Other Costof Revenue
----------$12.5B$12.8B$13.7B
Other Gain Loss From Disposition Of Discontinued Operations
--$4.6B------------
Other Gand A
$16.5B--------------
Realized Capital Gain
$2.4B--------------
Rent And Landing Fees
$15.7B--------------
Selling Expense
$13.7B$14.4B$14.2B----------
Write Down
$603.0M$-752.0M$-702.0M----------
Restruct
$3.2B--------------

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2NVS$150.62-0.9%884.18K
3
4
5
6

Get Novartis AG Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.